Ritter Pharmaceuticals Stock Price - RTTR

0.0059 (2.53%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ritter Pharmaceuticals Inc RTTR NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.0259 12.51% 0.2329 0.19 0.247 0.20 0.207 00:00:04
Bid Price Ask Price Spread Spread % News
0.22 0.24 0.02 8.33% 2 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
19,170 24,562,540 $ 0.2185134 $ 5,367,244 6,083,686 0.141 - 1.35
Last Trade Time Type Quantity Stock Price Currency
19:58:58 formt 300 $ 0.2388 USD

Ritter Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 7.61M 32.67M $ -16.87M -3.64 - 32.53M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Ritter Pharmaceuticals News

Loading Messages....

Latest RTTR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RTTR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1950.2470.180.19702973,881,7230.037919.44%
1 Month0.1990.250.180.21351974,529,4700.033917.04%
3 Months0.19470.330.1410.21150454,754,9450.038219.62%
6 Months0.95091.230.1410.24153242,626,649-0.718-75.51%
1 Year0.66121.350.1410.33647911,523,493-0.4283-64.78%
3 Years32.5033.900.1411.99785,209-32.27-99.28%
5 Years50.0054.9990.1413.37537,272-49.77-99.53%

Ritter Pharmaceuticals Description

Ritter Pharmaceuticals Inc develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

Your Recent History
Ritter Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.